BR0214340A - Method for controlling angiogenesis in animals - Google Patents

Method for controlling angiogenesis in animals

Info

Publication number
BR0214340A
BR0214340A BR0214340-2A BR0214340A BR0214340A BR 0214340 A BR0214340 A BR 0214340A BR 0214340 A BR0214340 A BR 0214340A BR 0214340 A BR0214340 A BR 0214340A
Authority
BR
Brazil
Prior art keywords
animals
angiogenesis
polymeric structure
controlling angiogenesis
therapeutic materials
Prior art date
Application number
BR0214340-2A
Other languages
Portuguese (pt)
Inventor
Yan Chang
Vodek Sasak
Original Assignee
Glycogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycogenesys Inc filed Critical Glycogenesys Inc
Publication of BR0214340A publication Critical patent/BR0214340A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

"MéTODO PARA CONTROLE DA ANGIOGêNESE EM ANIMAIS". As condições de doenças que são dependentes ou moderadas pela angiogênese são controladas pelo uso de um material terapêutico que interage com galectinas da superfície celular. Materiais terapêuticos particulares compreendem uma estrutura polimérica que apresenta cadeias laterais com extremidade ligada a um açúcar. Os materiais terapêuticos específicos estão descritos onde a estrutura polimérica é composta de ácido poligalacturónico e a extremidade das cadeias laterais em arabinose ou galactose."ANGIOGENESIS CONTROL METHOD IN ANIMALS". Disease conditions that are dependent or moderated by angiogenesis are controlled by the use of a therapeutic material that interacts with cell surface galectins. Particular therapeutic materials comprise a polymeric structure having sugar-linked end chains. Specific therapeutic materials are described wherein the polymeric structure is composed of polygalacturonic acid and the end of the arabinose or galactose side chains.

BR0214340-2A 2001-11-21 2002-11-21 Method for controlling angiogenesis in animals BR0214340A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33179301P 2001-11-21 2001-11-21
US10/299,478 US6890906B2 (en) 2001-11-21 2002-11-19 Method for controlling angiogenesis in animals
PCT/US2002/037400 WO2003045908A2 (en) 2001-11-21 2002-11-21 Method for controlling angiogenesis in animals

Publications (1)

Publication Number Publication Date
BR0214340A true BR0214340A (en) 2004-09-14

Family

ID=26971240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214340-2A BR0214340A (en) 2001-11-21 2002-11-21 Method for controlling angiogenesis in animals

Country Status (10)

Country Link
US (1) US6890906B2 (en)
EP (1) EP1451227A4 (en)
JP (1) JP2005521644A (en)
CN (1) CN1636020A (en)
AU (1) AU2002348316A1 (en)
BR (1) BR0214340A (en)
CA (1) CA2467451A1 (en)
IL (1) IL161763A0 (en)
MX (1) MXPA04004873A (en)
WO (1) WO2003045908A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
AU2004229399B2 (en) 2003-04-07 2010-08-05 Prospect Therapeutics, Inc. Composition and uses of galectin antagonists
US20050158321A1 (en) * 2003-12-17 2005-07-21 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
CA2582428A1 (en) * 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2006017356A1 (en) * 2004-07-13 2006-02-16 Glycogenesys, Inc. Method for treating neurodegenerative diseases
US9427449B2 (en) * 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
FR2916353B1 (en) * 2007-05-25 2010-09-24 Univ Picardie PHARMACEUTICAL COMPOSITION FOR PRESERVING COLLAGEN
BR112014015940B1 (en) 2011-12-28 2022-08-09 Galectin Therapeutics, Inc PHARMACEUTICAL GRADE POLYSACCHARIDE, COMPOSITION, AND THEIR USES
US9763974B2 (en) 2012-06-06 2017-09-19 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
WO2014043708A1 (en) 2012-09-17 2014-03-20 Traber Peter G Method for enhancing specific immunotherapies in cancer treatment
CA2926917C (en) 2012-10-10 2021-01-05 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP6366598B2 (en) * 2012-11-15 2018-08-01 タフツ ユニバーシティー Methods, compositions, and kits for treating, modulating, or preventing angiogenesis or fibrosis in a subject's eye using a galectin protein inhibitor
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
KR20160122855A (en) * 2014-03-10 2016-10-24 라 졸라 파마슈티칼 컴파니 Compositions and methods for treating kidney disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6632797B2 (en) * 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
CA2279791C (en) 1998-08-14 2011-11-08 Marcus B. Gohlke Dietary supplement combining colostrum and lactorferrin in a mucosal delivery format
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies

Also Published As

Publication number Publication date
EP1451227A2 (en) 2004-09-01
WO2003045908A3 (en) 2003-08-07
CN1636020A (en) 2005-07-06
AU2002348316A1 (en) 2003-06-10
JP2005521644A (en) 2005-07-21
WO2003045908A2 (en) 2003-06-05
EP1451227A4 (en) 2005-06-15
US20030100535A1 (en) 2003-05-29
IL161763A0 (en) 2005-11-20
MXPA04004873A (en) 2004-07-30
US6890906B2 (en) 2005-05-10
CA2467451A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
BR0214340A (en) Method for controlling angiogenesis in animals
ES2096565T3 (en) COMPOSITIONS AND METHODS FOR WATERPROOFING STRUCTURES FORMED WITH WATERPROOF CONSTRUCTION MATERIALS.
DE69429015T2 (en) CEMENT CONCRETE REINFORCED WITH RUBBER CRUMBS
SE8901508D0 (en) ANCHOR ANIMALS FOR PREPARING MEMBRANCE STRUCTURES USED BY LED MECHANISMS WHICH SAID TO APPLY ANCHORING ELEMENT IN BONE WEB REFERRED USE OF A DOUBLE ANCHORING ELEMENT
BRPI0417980A (en) fabric for use in a cladding for a building structure
BR0014125A (en) Halogenated terpolymers of isobutylene, diolefin monomer and styrenic monomer
PT1012422E (en) CEMENT PANEL WITH REFORCED LIDS
BRPI0410884A (en) feed composition for use in a pet, and method for weight control in a pet
SE9103101L (en) FIRE-SAFE TAECK MATERIAL
ES2167896T3 (en) SUPERFICIALLY MODIFIED LOADS, OF TYPE OXIDE OR SILICATE AND ITS USE.
EA199801070A1 (en) SUSTAINABILITY OF BRIDGES
CA2035895A1 (en) Lifting cramp, mainly for raising concrete slabs
BR9814896A (en) Process for the preparation of water-soluble or swellable polymers in water with very low remaining monomer content, products prepared by it and their use
SE7702697L (en) FIXING ELEMENT FOR WOOD, LIGHT CONCRETE, PLASTER, ETC.
FR2638743B1 (en) METHYL-2 TERTIOBUTYL-5 THIOPHENOL, ITS PREPARATION METHOD AND ITS APPLICATION
ATE65771T1 (en) PLASTER SYSTEM.
ATE74579T1 (en) SELF-LEVELLING MORTAR MIX.
ES2067288T3 (en) PAINTINGS FOR FACADES AND PLASTERS WITH HIGH RESISTANCE TO EARLY WATER.
PT1216035E (en) PREPARATION CONTAINING ACTIVE INGREDIENTS AND / OR AUXILIARY AGENTS WITH A CONTROLLED RELEASE OF THESE SUBSTANCES AND THE USE AND PRODUCTION THEREOF
ATE23033T1 (en) STABLE CEMENT COMPOSITION.
BRPI0415366A (en) long-acting composition to control parasites internal and external to animals, and use of the same
BR9105923A (en) COMPOSITION FOR USE AS AN AUXILIARY WATER RINSE SOLUTION OR DISPERSION IN THE TREATMENT OF PLASTIC OR PAINTED SURFACES, MIXING SURFACES, SOLUTION OR DISPERSION, WATER OF A COMPOSITION, AND, PROCESS FOR THE TREATMENT OF OPERATED PLASTICS
DK1072397T3 (en) Exterior building board consisting of a core and at least one reinforced mortar layer
NO903321L (en) WATER UNWARNED SKINS THAT ARE BIOLOGICALLY STABLE AND PROCEDURE FOR THEIR PREPARATION.
ES2093726T3 (en) THERMAL INSULATION MATERIAL FOR FIRE PROTECTION CONSTRUCTIONS.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2034 DE 29/12/2009.